As a board-certified hematologist/oncologist I have a clinical focus on patients with hematologic diseases, specifically leukemia and myelodysplastic syndrome, and on those who may benefit from any form of stem cell transplantation.
Patients who undergo transplant usually spend most of their time after transplantation in the outpatient department, so my role as Clinical Director of Memorial Sloan Kettering’s Adult Bone Marrow Transplant Outpatient Unit affords me the opportunity to improve the experience of all of our transplant patients.
Over the past several years my research has involved new approaches to transplantation that reduce transplant-related complications and enhance patients’ immune reconstitution after transplant. These approaches are making transplantation an option for new and expanding populations of patients. This research has also been integral to our developing an adult Survivorship Program for stem cell transplant patients, and has instigated the development of Memorial Sloan Kettering’s 65+ Program for older adults.
In collaboration with colleagues throughout the Center, physicians of the 65+ Program created an assessment tool for older adult patients which is now used by cancer centers throughout the country to evaluate patients prior to treatment. This tool is being incorporated into the screening of older adult patients prior to transplant to assist the physicians in selecting the type of transplant best suited to each patient.
In our Survivorship Clinic, where patients who have undergone transplant receive follow-up care, we have established a program to monitor post-transplant complications in patients of all ages. By reviewing characteristics and outcomes of patients who have already undergone transplant with subspecialists in all of the major medical areas, we identify complications; adapt our screening, treatment, and monitoring programs; and conduct research to improve these outcomes. The results of this monitoring program are being used to help design studies of new transplant methods and to alter transplants to reduce the time that a patient’s immune system is suppressed afterward.
On the national level, my membership on an expert committee for tissue, gene, and cell therapy of the United States Pharmacopeia (USP) — a non-governmental, official public standards-setting authority for healthcare products — has given me the opportunity to participate in the process of standardizing treatment modalities that are at the forefront of medical care and transplantation.
- Clinical Expertise: Acute and Chronic Leukemia; Myelodysplastic Syndrome; Adult Stem Cell Transplantation
- Languages Spoken: English
- Education: MD, University of Connecticut Medical School
- Residencies: Internal Medicine - Mount Sinai Medical Center
- Fellowships: Hematology - Montefiore Medical Center/Albert Einstein Medical Center; Hematology/Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Hematology; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Ann A. Jakubowski
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more